Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Authors:
Top Cited Papers
- 19 January 2022
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 21 (2) , 125-139
Abstract
No abstract availableKeywords
Funding Information
- Idorsia Pharmaceuticals Ltd
This publication has 24 references indexed in Scilit:
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of PhysiciansAnnals of Internal Medicine, 2016
- Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical TrialsBiological Psychiatry, 2016
- Insomnia disorderNature Reviews Disease Primers, 2015
- Differential sleep-promoting effects of dual orexin receptor antagonists and GABAAreceptor modulatorsBMC Neuroscience, 2014
- The subjective–objective mismatch in sleep perception among those with insomnia and sleep apneaJournal of Sleep Research, 2013
- Almorexant Promotes Sleep and Exacerbates Cataplexy in a Murine Model of NarcolepsySLEEP, 2013
- “… Not Just a Minor Thing, It Is Something Major, Which Stops You From Functioning Daily”: Quality of Life and Daytime Functioning in InsomniaBehavioral Sleep Medicine, 2010
- A graphical approach to sequentially rejective multiple test proceduresStatistics in Medicine, 2008
- Focusing on the Experience of InsomniaBehavioral Sleep Medicine, 2005
- Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic systemJournal of Comparative Neurology, 1999